Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;82(4):477-484.
doi: 10.1007/s40265-022-01690-7.

Sotrovimab: First Approval

Young-A Heo  1
Affiliations
Review

Sotrovimab: First Approval

Young-A Heo. Drugs. 2022 Mar.

Abstract

Sotrovimab (Xevudy®) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Vir Biotechnology in collaboration with GlaxoSmithKline for the treatment of coronavirus disease 2019 (COVID-19). Sotrovimab received its first emergency use authorization in May 2021 for the treatment of COVID-19 in the USA, with interim, emergency or conditional authorizations subsequently granted in several other countries. In December 2021, sotrovimab received its first full approval in the EU for use in adolescents (aged ≥ 12 years and weighing ≥ 40 kg) and adults with COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19. This article summarizes the milestones in the development of sotrovimab leading to this first approval.

PubMed Disclaimer

Conflict of interest statement

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Young-A Heo is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Figures

None
Key milestones in the development of sotrovimab for the treatment of COVID-19. *Evaluation of other monoclonal antibodies is ongoing; the estimated completion date of ACITV-3 is July 2022.
See this image and copyright information in PMC

References

    1. Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081–1089. doi: 10.1001/jamainternmed.2020.2033. - DOI - PMC - PubMed
    1. National Institutes of Health. Therapeutic management of nonhospitalized adults with COVID-19. 2022. https://www.covid19treatmentguidelines.nih.gov/. Accessed 15 Feb 2022.
    1. Cathcart AL, Havenar-Daughton C, Lempp FA, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021:2021.03.09.434607.
    1. GlaxoSmithKline. Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant [media release]. 8 Dec 2021. http://www.gsk.com.
    1. US Food & Drug Administration. Emergency use authorization: sotrovimab. 2021. https://www.fda.gov. Accessed 25 Jan 2022.

LinkOut - more resources